In light of the low single agent activity of venetoclax in B cell lymphomas, combination regimens are now being evaluated, mostly in the context of the general strategy of adding venetoclax to well-recognized chemo-immunotherapy combination with established efficacy (bendamustine and rituximab; CHOP and rituximab; CHOP and obinutuzumab; EPOCH and rituximab), or highly promising new drugs (ibrutinib) (Tables 3, 4). Here, DDIT3 is linked to B-cell non-Hodgkin lymphoma.